The problem
A Brisbane cosmetic injectables clinic was three weeks into a paid campaign cycle when AHPRA's cosmetic guidance update landed. Existing creative — substance-side framing, transformation imagery, results testimonials — was structurally non-compliant under the revised standard. The clinic faced a campaign pause that would have written off six-figure spend.
The constraint
Cosmetic injectables sit at the most-watched intersection in healthcare advertising — AHPRA's tightened cosmetic guidance overlaying TGA s.42DLB on the substance itself. The 2024 update left every substance-led creative on the platform out of compliance overnight. The replacement had to ship in days, not weeks — before platform review paused the live campaigns and wrote off committed spend.
The approach
We knew the revised standard at brief stage because we had been tracking the consultation drafts. Replacement creative was pre-built procedure-side — consultation framing, practice environment, clinician-led narrative — and shipped through medico-legal review in parallel with platform re-submission. No substance, no transformation, no testimony.
The outcome
Revised creative shipped in five days, before the existing campaigns were paused at platform review. Six-figure committed spend was preserved across the transition window. The procedure-side creative has since outperformed the legacy substance-side creative on cost-per-consult by 22%.